Bleakley Financial Group LLC Takes $93,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Bleakley Financial Group LLC bought a new position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 48,108 shares of the company’s stock, valued at approximately $93,000.

Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. grew its position in Lyell Immunopharma by 352.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 29,137 shares of the company’s stock worth $57,000 after purchasing an additional 22,701 shares during the period. Public Employees Retirement System of Ohio increased its holdings in Lyell Immunopharma by 109.7% in the third quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock valued at $40,000 after buying an additional 14,229 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Lyell Immunopharma by 81.9% in the 4th quarter. SG Americas Securities LLC now owns 99,221 shares of the company’s stock valued at $192,000 after purchasing an additional 44,686 shares in the last quarter. Profund Advisors LLC raised its holdings in Lyell Immunopharma by 20.0% in the 3rd quarter. Profund Advisors LLC now owns 73,442 shares of the company’s stock worth $108,000 after purchasing an additional 12,225 shares during the period. Finally, Citigroup Inc. boosted its position in Lyell Immunopharma by 20.0% during the third quarter. Citigroup Inc. now owns 193,739 shares of the company’s stock worth $285,000 after purchasing an additional 32,225 shares in the last quarter. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright cut their price objective on Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, February 29th.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL opened at $2.41 on Wednesday. The firm has a fifty day moving average of $2.25 and a 200 day moving average of $2.00. The firm has a market cap of $612.38 million, a PE ratio of -2.59 and a beta of -0.55. Lyell Immunopharma, Inc. has a one year low of $1.32 and a one year high of $3.97.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative return on equity of 32.67%. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $4.96 million. On average, equities analysts predict that Lyell Immunopharma, Inc. will post -0.91 EPS for the current fiscal year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.